On April 27, 2026, Terns Pharmaceuticals announced that the FDA granted Breakthrough Therapy Designation to their therapy TERN-701 for treating adult patients with chronic myeloid leukemia. This designation highlights the therapy’s potential to significantly improve treatment outcomes based on encouraging clinical trial data.